Cathie Wood's ARK ETFs have made a series of trades on Wednesday, September 4th, 2024, with the most significant move being the sale of shares in CareDx Inc (NASDAQ:CDNA) and the purchase of a substantial number of shares in Recursion Pharmaceuticals Inc (NASDAQ:RXRX).
The ARK Genomic Revolution ETF (ARKG) sold 25,791 shares of CareDx, a molecular diagnostics company, valued at approximately $758,513. This transaction follows a pattern of selling for CareDx, as ARK has been reducing its holdings in the company since last week.
On the buying side, ARK's flagship fund, the ARK Innovation ETF (ARKK), along with ARKG, acquired a combined total of 726,505 shares of Recursion Pharmaceuticals, a biotech firm specializing in drug discovery, for a dollar value of $4,409,885. This is a continuation of ARK's investment strategy in Recursion, as they have consistently added to their position in recent days.
The ARK Space Exploration & Innovation ETF (ARKX) sold 12,978 shares of Mynaric AG (NASDAQ:MYNA), a provider of laser communication technologies for air and space applications, for a total of $12,134. This follows a minor sale of the same stock the previous day.
In addition, ARK offloaded 31,244 shares of The Trade Desk Inc (NASDAQ:TTD), a provider of a global technology platform for buyers of advertising, across ARKK and ARK Next Generation Internet ETF (ARKW) for a total of $3,154,706. This move comes on the heels of a significant sale of The Trade Desk shares on the previous Friday.
Other sales included Garmin Ltd (NASDAQ:NYSE:GRMN), 908 Devices Inc. (NASDAQ:MASS), Materialise NV (NASDAQ:MTLS), Unity Software Inc (NYSE:NYSE:U), Veracyte Inc (NASDAQ:VCYT), Verve Therapeutics Inc (NASDAQ:VERV), and Vuzix Corp (NASDAQ:VUZI), with total values ranging from $79 to $2,175,215.
On the acquisition front, ARK also added to its holdings in Oklo Inc (NASDAQ:OKLO) through the ARK Autonomous Technology & Robotics ETF (ARKQ), purchasing 62,838 shares valued at $351,264.
Investors following ARK's trading activities have noted the continued interest in innovative healthcare and technology companies, with a keen eye on the long-term potential of these sectors. The daily trade report from ARK is closely watched as an indicator of where the influential investment firm sees future growth opportunities.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.